Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s first-on ...

CEO Emma Walmsley says. Speaking at the CEO Times Summit in London, Walmsley highlights the U.K. pharmaceutical company's refocused R&D strategy, with investments concentrated in the U.K., U.S ...

Emma Walmsley has also been busy shaking up the company and has replaced 50 top managers, around 40% of the company’s management. Pfizer said in October that it is considering selling its ...